Navigation Links
ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
Date:12/17/2009

The primary endpoint of the study is the proportion of patients who achieve undetectable levels of virus at week 12 (defined as complete Early Virological Response, or cEVR). Additional endpoints include safety and tolerability as well as the proportion of patients with undetectable levels of virus at week 4 (defined as Rapid Virological Response, or RVR). Patients will be followed for 24 weeks after stopping therapy to determine the rate of Sustained Virological Response, or SVR. Approximately 90 patients are planned to be enrolled in this study - with approximately 30 patients receiving ANA598 and 15 receiving placebo at each dose level.

The study is being managed by the Duke Clinical Research Institute (DCRI) under the leadership of John McHutchison, M.D. and is being conducted at a number of clinical sites in the United States. An independent DMC is responsible for reviewing the safety data in the trial and has endorsed escalating to the second dose level of 400 mg bid. This cohort is now open for enrollment and Anadys expects to initiate dosing in January 2010.

About ANA598

ANA598 is a non-nucleoside inhibitor of the HCV RNA polymerase and is wholly owned by Anadys. Anadys has completed three Phase I clinical studies of ANA598 that have demonstrated potent antiviral activity and good tolerability. In a monotherapy study in treatment-naïve genotype 1 patients, treatment with ANA598 for three days led to median end-of-treatment declines in viral load ranging from 2.4 to 2.9 log10 in three separate dose groups. No patient at any dose level showed evidence of viral rebound while on ANA598, and there were no serious adverse events. Those patients from the monotherapy study who subsequently received pegylated interferon and ribavirin all exhibited further viral load decline, demonstrating that viral variants revealed by brief treatment with A
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
11. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 Just days before the government of ... contain the spread of Ebola, World Vision will begin a ... thanks to private donations. McKesson, the largest healthcare ... through its affiliate McKesson Medical-Surgical donated four million pairs of ... Sierra Leone,s needs for the next ...
(Date:9/18/2014)... AMSTERDAM , September 18, 2014 ... in economic growth, and the situation is most likely to ... Atradius is observing an impact across all sectors in the ... a rise in inflation, limited access to external financing and ... could experience an increase in payment delays and ...
(Date:9/18/2014)... VIEW, Calif. and CHESTERBROOK, Pa. ... (Nasdaq: VVUS ) and Auxilium Pharmaceuticals, Inc. ... U.S. Food and Drug Administration (FDA) has approved a supplemental ... is now the only FDA-approved erectile dysfunction (ED) medication indicated ... sexual activity. STENDRA is a prescription medication in ...
Breaking Medicine Technology:World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 2World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 3World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 4Exporters to Russia Facing Increasing Payment Risk 2VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 2VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 3VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 4VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 5VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 6VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 7VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 8VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 9
... 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... to reprise key carfilzomib data presentations that were featured at ... San Diego, California. The teleconference will begin at ... Interested parties may access the teleconference and the presentation that ...
... /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... diagnostic ("IVD") company, responded today to the allegations raised ... dated December 6, 2011. The Company maintains that the ... "Report") concern matters which have long been disclosed in ...
Cached Medicine Technology:China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 2China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 3China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 4China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 5China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 6
(Date:9/18/2014)... Los Angeles, CA (September 18, 2014) Cardiovascular disease ... high cholesterol plays a major role in accelerating ... as a treatment to decrease cholesterol-carrying lipoproteins such ... especially harmful. A new study, out today in ... finds that rosuvastatin may be more effective ...
(Date:9/18/2014)... OR (PRWEB) September 18, 2014 Eye doctors ... hours can cause the all-important basal tear film in the ... recently reported in Salon.com* suggests that staring at a computer ... has been teaching her audience about computers, the tear film ... as an affirmation. , (*Gray, Sarah, “Staring at Screen ...
(Date:9/18/2014)... Sutter Health’s California Pacific Medical Center (CPMC) ... by naming the Ray Dolby Brain Health Center in ... a founding gift of $21 million in 2011 to ... patients and families suffering from Alzheimer’s, dementia or other ... at the center since its opening in 2012. ...
(Date:9/18/2014)... 18, 2014 Choosing the insulation for the ... a big deal to most homeowners, but Clean Crawls’ ... In their expert opinion, they explain why spray foam insulation ... care of their crawl space. , They highlight not ... but also its air tight seal and moisture protective abilities. ...
(Date:9/18/2014)... Baltimore, MD (PRWEB) September 18, 2014 A ... body shaping system has been approved by the United States ... yet available for widespread purchase in the US, landmark dermatology ... first and only practices on the east coast to use ... the only practice in the Baltimore area to offer patients ...
Breaking Medicine News(10 mins):Health News:New Study Confirms that Staring at a Computer Screen Alters Tear Film Content and Causes Dry Eye 2Health News:New Study Confirms that Staring at a Computer Screen Alters Tear Film Content and Causes Dry Eye 3Health News:Sutter Health’s CPMC announces Ray Dolby Brain Health Center 2Health News:Sutter Health’s CPMC announces Ray Dolby Brain Health Center 3Health News:Why Spray Foam Insulation is the Best Choice for Crawl Spaces Explained in Recent Article by Clean Crawls 2Health News:New FDA-Approved UltraShape Body Contouring Procedure Comes to Maryland Laser Skin and Vein 2
... Attributes proprietary database and technology for its 296 ... HTH Worldwide, a global health and,safety services company, ... for Greater Philadelphia, a ranking of the 50 ... in the,area by Deloitte LLP, one of the ...
... ANN ARBOR, Mich., Oct. 31 Terumo Heart ... System (LVAS) was,implanted in October at the University ... efforts toward an early application for approval,for manufacture ... the world,s first third generation left ventricular,assist system ...
... Oct. 31 Relaxation specialists,Lifehut.com, have released their ... "Finding Joy During Challenging Financial,Times.", Aimed at ... to allow people to enter an alpha state ... much going on in our economy, job layoffs ...
... its 5,000 Percent Revenue Growth from FY03-FY07 to Increased ... ... Accuray,Incorporated (Nasdaq: ARAY ), has been named to ... companies. This year,s Silicon Valley Technology Fast 50,program is co-presented ...
... Natural health news site,NaturalNews.com has teamed with ... omega-3 supplement to health-conscious consumers. Made,from green-lipped mussel ... of,New Zealand, Moxxor is a nutrient-rich marine omega-3 ... to enhance and support the,body,s healthy response to ...
... million (+30%y/y), EPS $0.23 (+44% y/y) - ... ... YORK, Oct. 31 HMS Holdings Corp. (Nasdaq:,HMSY) today announced its financial ... For the quarter ended September 30, 2008 revenue increased 30% to $49.0,million, ...
Cached Medicine News:Health News:HTH Worldwide Ranked Number 21 in Deloitte's Fast 50 Program for Greater Philadelphia 2Health News:HTH Worldwide Ranked Number 21 in Deloitte's Fast 50 Program for Greater Philadelphia 3Health News:Lifehut.com Aims to Relax the Financially Stressed 2Health News:Accuray Incorporated Ranked Fifth in Deloitte's Technology Fast 50 Program for Silicon Valley Scientific/Medical Equipment, and Biotechnology Companies 2Health News:Accuray Incorporated Ranked Fifth in Deloitte's Technology Fast 50 Program for Silicon Valley Scientific/Medical Equipment, and Biotechnology Companies 3Health News:Accuray Incorporated Ranked Fifth in Deloitte's Technology Fast 50 Program for Silicon Valley Scientific/Medical Equipment, and Biotechnology Companies 4Health News:NaturalNews Partners with Moxxor to Bring Marine Omega-3 Supplement to Health-Conscious Consumers 2Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 2Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 3Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 4Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 5Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 6Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 7Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 8Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 9Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 10
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: